Replimune Group Inc (REPL)
🔔 Watch stock
Replimune builds viruses meant to blow tumors open from the inside — one of the most exciting ideas in cancer medicine. Only, the company earns not a single dollar from it so far. The stock shows up in our going-concern warning scanner, and its own annual report confirms exactly that: we read the 10-K for fiscal year 2026 and the quarterly report (10-Q) — $1.26 billion in accumulated losses, a till that per the auditor lasts only into early 2027, an explicit doubt about survival, and two FDA rejections for the cancer therapy RP1. Still the price jumped 153 percent in two months. Not investment advice — just a sober cash count before the big date.
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.68 | – | 0 | – | – | -39 | -41 |
| 2024: Q4 | -0.79 | – | 0 | – | – | -51 | -53 |
| 2025: Q1 | -0.92 | – | 2 | -63.60 | -5,036.00 | -54 | -55 |
| 2025: Q2 | -0.95 | – | 0 | – | – | -77 | -80 |
| 2025: Q3 | -0.90 | – | 0 | – | – | -81 | -83 |
| 2025: Q4 | -0.77 | – | 0 | – | – | -66 | -66 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Assessment: Opportunities & Risks
Oncolytic immunotherapy on its own RPx platform (HSV-1) is one of the most exciting ideas in cancer medicine; the lead drug RP1 is tested in the IGNYTE trial against advanced melanoma, combined with nivolumab, which Bristol Myers Squibb contributes free of charge (annual report 10-K 2026).
The auditor has issued a going-concern note: the cash ($268.9 million as of March 31, 2026) lasts, per the company, only into the first calendar quarter of 2027, against an operating cash outflow of $280.3 million in fiscal year 2026 and with no committed further financing.
No product revenue since inception; the net loss rose in three fiscal years from $66.6 to $313.9 million, the accumulated deficit stands at $1,262.5 million — more than the entire market weight. The stock's value is entirely a bet on a future approval.
Two rejection notices (CRL) in July 2025 and April 2026 — the second contradicted, per the company, an earlier FDA position. On June 26, 2026 the FDA accepted the resubmission with an action date of August 2, 2026 and an advisory committee in late July 2026: a binary event with an open outcome.
Plus 153 percent in two months and plus 642 percent above the 52-week low, carried by the approval hope; about 97 percent institutional ownership. At the same time technical scanners rate the rally as a topping formation (Weinstein Stage 3) and "overheated" — an altitude rush next to a going-concern note.
Replimune is not a case of substance versus story, but a pure bet with clear conditions: a fascinating cancer technology and a tangible FDA date of August 2, 2026 on one side — on the other an auditor who doubts survival in black and white, not a cent of revenue, $1.26 billion in accumulated losses, two regulatory rejections and a workforce cut of about 55 percent. The stock is a warrant on a single yes or no. Not investment advice.
- Replimune's fiscal year ends on March 31; annual figures refer to the respective fiscal year (e.g. "2026" = April 1, 2025 through March 31, 2026). Program and trial milestones, by contrast, the company reports on a calendar-year basis.
- All earnings and balance-sheet figures come from the audited annual report 10-K for the fiscal year ended March 31, 2026 as well as the quarterly reports; the FDA date status (August 2, 2026) is the status stated in the 10-K.
- Price and valuation figures dated to July 8, 2026 (about $11); analyses are evergreen, daily prices are not a buy argument.
About the Company
Replimune Group, Inc., ein Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung und Vermarktung onkolytischer Immuntherapien zur Krebsbehandlung.
| IPO Year | 2018 |
|---|---|
| Next Earnings | 2. Jul 2026 |
Chart
Data as of: July 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.